The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results